Get the Stockscreener App
2.64
5.04%
-0.14
After Hours:
2.64
Spero Therapeutics Inc stock is traded at $2.64, with a volume of 693.53K.
It is down -5.04% in the last 24 hours and up +2.33% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.78
Open:
$2.78
24h Volume:
693.53K
Relative Volume:
2.00
Market Cap:
$152.83M
Revenue:
$59.62M
Net Income/Loss:
$8.57M
P/E Ratio:
22.18
EPS:
0.119
Net Cash Flow:
$-12.62M
1W Performance:
-2.94%
1M Performance:
+2.33%
6M Performance:
+6.02%
1Y Performance:
+254.65%
1-Day Range:
$2.63
$2.80
1-Week Range:
$2.625
$2.88
52-Week Range:
$0.57
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.64 | 160.94M | 59.62M | 8.57M | -12.62M | 0.119 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Spero Therapeutics (NASDAQ: SPRO) asks shareholders to double authorized shares to 240M - Stock Titan
Portfolio Shifts: Is Spero Therapeutics Inc stock showing strong momentum2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
MACD Signal: Does Spero Therapeutics Inc have pricing power2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
Market Overview: Will Spero Therapeutics Inc benefit from seasonality2026 Pullbacks & Capital Efficiency Focused Ideas - baoquankhu1.vn
Market Review: What is the PEG ratio of Spero Therapeutics IncInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
Spero Therapeutics Stock Rises Above 50-Day Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics Secures Financial Stability Through 2028 () - aktiencheck.de
Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast - Defense World
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives - Sahm
Spero Therapeutics shares jump over 4% on better-than-expected Q4 print - Investing.com
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - Bitget
Spero Therapeutics earnings beat by $0.73, revenue topped estimates - Investing.com Canada
SPERO THERAPEUTICS ($SPRO) Releases Q4 2025 Earnings - Quiver Quantitative
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.73 EPS - MarketBeat
Spero Therapeutics Q4 revenue nearly triples, swings to profit - TradingView
Spero Therapeutics 2025 10-K: $66.8M Revenue, $0.15 EPS - TradingView
Spero Therapeutics (NASDAQ: SPRO) turns 2025 profit as tebipenem advances - Stock Titan
BRIEF-Spero Therapeutics Q4 EPS USD 0.56 - TradingView
[10-K] Spero Therapeutics, Inc. Files Annual Report - Stock Titan
Can Spero Therapeutics Inc sustain earnings growth2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Spero Therapeutics shares jump over 4% on better-than-expected Q4 print By Investing.com - Investing.com South Africa
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround - MSN
Analyst Calls: Is Spero Therapeutics Inc stock showing strong momentumWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
If You Invested $1,000 in Spero Therapeuti (SPRO) - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Spero Therapeutics (SPRO.US) will release its earnings report after the market closes on March 26. - 富途牛牛
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Activity Recap: Is Spero Therapeutics Inc stock showing strong momentumPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday - MarketBeat
Spero Therapeutics Inc 預計每股虧損 55 美分財報前瞻 - TradingView
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - marketscreener.com
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Spero Therapeutics to post Q4 and 2025 results on March 26 - Stock Titan
Weekly Earnings: What are Spero Therapeutics Incs recent SEC filings showingQuarterly Trade Report & Capital Efficient Trading Techniques - baoquankhu1.vn
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Decline in Short Interest - MarketBeat
Profit Recap: Is Spero Therapeutics Inc stock showing strong momentumStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Spero Therapeutics Inc erwartet einen Verlust von 55 Cents pro AktieEarnings Preview - TradingView
Dow Update: Can Spero Therapeutics Inc lead its sector in growth2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Stock Recap: Can Spero Therapeutics Inc ride the EV waveMarket Movers & Daily Chart Pattern Signals - baoquankhu1.vn
Big Picture: Will Spero Therapeutics Inc benefit from seasonalityWeekly Profit Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Declines By 24.0% - MarketBeat
SPRO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can Spero Therapeutics Inc. (2HA) stock sustain margin levels2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):